LAVA Therapeutics NV
(NASDAQ : LVTX)

( )
LVTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. 0.83%745.682.6%$767.75m
AMGNAmgen, Inc. 0.34%233.821.4%$621.98m
MRNAModerna, Inc. -0.04%125.620.0%$612.25m
BIIBBiogen, Inc. -2.15%261.691.8%$573.08m
GILDGilead Sciences, Inc. 0.21%65.451.0%$559.47m
VRTXVertex Pharmaceuticals, Inc. 0.46%302.021.9%$432.92m
ILMNIllumina, Inc. 6.56%218.523.2%$428.55m
SNSSSunesis Pharmaceuticals, Inc. -1.21%4.080.7%$285.21m
SAVACassava Sciences, Inc. -1.80%40.970.0%$181.06m
BNTXBioNTech SE -0.28%137.190.0%$112.04m
TECHBio-Techne Corp. 0.00%308.554.5%$100.54m
BMRNBioMarin Pharmaceutical, Inc. 1.84%89.534.2%$90.99m
NVAXNovavax, Inc. -3.61%18.7075.6%$84.10m
PRTAProthena Corp. Plc 1.15%58.1113.8%$78.29m
CRSPCRISPR Therapeutics AG -1.58%64.630.6%$77.63m

Company Profile

LAVA Therapeutics NV operates as an immuno-oncology company. It utilizing its proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.